User profiles for V. W. Rebecca

vito rebecca

Verified email at wistar.org
Cited by 14252

[HTML][HTML] Pre-clinical modeling of cutaneous melanoma

VW Rebecca, R Somasundaram, M Herlyn - Nature communications, 2020 - nature.com
Metastatic melanoma is challenging to manage. Although targeted- and immune therapies
have extended survival, most patients experience therapy resistance. The adaptability of …

Emerging strategies to effectively target autophagy in cancer

VW Rebecca, RK Amaravadi - Oncogene, 2016 - nature.com
Autophagy serves a dichotomous role in cancer and recent advances have helped delineate
the appropriate settings where inhibiting or promoting autophagy may confer therapeutic …

A brief history of melanoma: from mummies to mutations

VW Rebecca, VK Sondak, KSM Smalley - Melanoma research, 2012 - journals.lww.com
In recent years, melanoma research has undergone a renaissance. What was once viewed,
at least in the metastatic setting, as an intractable and untreatable disease is now revealing …

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

KHT Paraiso, Y Xiang, VW Rebecca, EV Abel, YA Chen… - Cancer research, 2011 - AACR
This study addresses the role of PTEN loss in intrinsic resistance to the BRAF inhibitor
PLX4720. Immunohistochemical staining of a tissue array covering all stages of melanocytic …

Stromal changes in the aged lung induce an emergence from melanoma dormancy

…, DA Maranto, SM Douglass, MR Webster, VW Rebecca… - Nature, 2022 - nature.com
Disseminated cancer cells from primary tumours can seed in distal tissues, but may take several
years to form overt metastases, a phenomenon that is termed tumour dormancy. Despite …

[HTML][HTML] Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy

…, X Zhou, A Gutierrez, VW Rebecca… - Nature …, 2021 - nature.com
Anti-PD-1 therapy is used as a front-line treatment for many cancers, but mechanistic insight
into this therapy resistance is still lacking. Here we generate a humanized (Hu)-mouse …

PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer

VW Rebecca, MC Nicastri, C Fennelly, CI Chude… - Cancer discovery, 2019 - AACR
VW Rebecca and MC Nicastri contributed equally to this article. … Writing, review, and/or
revision of the manuscript: VW Rebecca, MC Nicastri, C. Fennelly, JS Barber-Rotenberg, A. …

The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms

KHT Paraiso, HE Haarberg, E Wood, VW Rebecca… - Clinical cancer …, 2012 - AACR
Purpose: The clinical use of BRAF inhibitors is being hampered by the acquisition of drug
resistance. This study shows the potential therapeutic use of the HSP90 inhibitor (XL888) in six …

[HTML][HTML] Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

…, J Wickramasinghe, AV Kossenkov, VW Rebecca… - Nature …, 2021 - nature.com
Patient-derived xenografts (PDXs) are resected human tumors engrafted into mice for preclinical
studies and therapeutic testing. It has been proposed that the mouse host affects tumor …

A unified approach to targeting the lysosome's degradative and growth signaling roles

VW Rebecca, MC Nicastri, N McLaughlin, C Fennelly… - Cancer discovery, 2017 - AACR
Lysosomes serve dual roles in cancer metabolism, executing catabolic programs (ie, autophagy
and macropinocytosis) while promoting mTORC1-dependent anabolism. Antimalarial …